You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

Details for Patent: 10,874,665


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,874,665
Title:Bupropion as a modulator of drug activity
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s): Tabuteau; Herriot (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:16/823,807
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,874,665: A Detailed Analysis

Introduction

Patent 10,874,665, like any other patent, is a complex document that outlines the intellectual property rights of an invention. To fully comprehend its scope and claims, it is essential to delve into the specifics of the patent, the current patent landscape, and recent updates in patent law.

Patent Overview

United States Patent 10,874,665 is a specific patent that, while not detailed in the provided sources, can be analyzed using general principles of patent law and recent updates.

Claim Structure and Scope

Independent and Dependent Claims

Patent claims are the heart of any patent application, defining the scope of the invention. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[3].

Claim Length and Count

Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims are associated with a higher probability of grant and a shorter examination process[3].

Subject Matter Eligibility

The 2024 USPTO guidance update on AI patent eligibility is crucial for understanding how claims are evaluated.

Judicial Exceptions and Practical Applications

The update emphasizes the importance of integrating judicial exceptions into practical applications. Claims must show that the abstract idea or mathematical model is applied in a way that provides concrete benefits or solves specific problems in the relevant field. For example, a claim that merely uses a mathematical model to manipulate data without a specific application would be ineligible, whereas a claim that applies the model to improve the accuracy of voice commands in a hands-free environment would be eligible[1].

AI-Assisted Inventions

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Practical Applications and Technological Improvements

Real-World Applications

Highlighting the real-world applications of the claimed method or system is crucial for demonstrating patent eligibility. For instance, if a claim specifies the use of separated audio components in a real-time speech recognition system to enhance the accuracy of voice commands, it provides a practical application that results in tangible benefits such as improved noise reduction and enhanced accuracy[1].

Technological Improvements

Claims must demonstrate a clear technological improvement. This involves showing that the claimed invention offers more than routine data processing steps. For example, a claim that improves related technical fields by specifying the use of separated audio components in a real-time speech recognition system would be considered patent-eligible because it provides a meaningful limit and integrates the judicial exception into a practical application[1].

Inventorship and Ownership

Determining True Inventors

US patent law requires that only the true and only inventors be listed on a patent application. This involves identifying those who conceived the idea and reduced it to practice. Incorrect or incomplete identification of inventors can lead to the patent being invalid and unenforceable[5].

Correction of Errors

While errors in inventorship can be corrected, deceptive intent in naming inventors can render the patent unenforceable. It is crucial to ensure thorough disclosure and accurate identification of inventors to maintain the enforceability of the patent[5].

Patent Landscape and Recent Updates

USPTO Guidance and Executive Orders

The 2024 USPTO guidance update, prompted by Executive Order 14110, aims to refine and clarify the process for determining the patent eligibility of AI-related inventions. This update provides examples and detailed eligibility analysis, helping practitioners to draft claims that are more likely to avoid section 101 rejections[1].

Global Dossier and Public Search Facilities

The USPTO offers various tools and services, such as the Global Dossier and the Public Search Facility, to assist in searching and managing patent applications. These resources help in understanding the patent family and related applications, which is essential for navigating the patent landscape[4].

Key Takeaways

  • Subject Matter Eligibility: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution.
  • Practical Applications: Highlighting real-world applications and technological improvements is crucial for demonstrating patent eligibility.
  • Inventorship: Accurate identification of true inventors is essential to maintain the enforceability of the patent.
  • Patent Scope: Narrower claims are associated with a higher probability of grant and a shorter examination process.

FAQs

  1. What is the significance of the 2024 USPTO guidance update on AI patent eligibility? The update refines and clarifies the process for determining the patent eligibility of AI-related inventions, providing examples and detailed eligibility analysis to help practitioners draft patent-eligible claims.

  2. How does the use of AI impact the patent eligibility of an invention? The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution. The focus remains on the claimed invention itself.

  3. What are the key elements for a claim to be considered patent-eligible? A claim must integrate a judicial exception into a practical application, providing concrete benefits or solving specific problems in the relevant field.

  4. Why is accurate inventorship important in patent applications? Accurate identification of true inventors is essential to maintain the enforceability of the patent. Incorrect or incomplete identification can lead to the patent being invalid and unenforceable.

  5. How can the USPTO's Global Dossier and Public Search Facilities aid in patent research? These resources help users access the file histories of related applications, see the patent family, and identify office actions, among other benefits, facilitating a more comprehensive understanding of the patent landscape.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent Eligibility - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO
  5. Determining Inventorship for US Patent Applications - Oregon State University

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,874,665

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Axsome AUVELITY bupropion hydrochloride; dextromethorphan hydrobromide TABLET, EXTENDED RELEASE;ORAL 215430-001 Aug 18, 2022 RX Yes Yes 10,874,665 ⤷  Try for Free DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,874,665

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014346807 ⤷  Try for Free
Australia 2015350559 ⤷  Try for Free
Australia 2018203638 ⤷  Try for Free
Australia 2019201548 ⤷  Try for Free
Australia 2019223187 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.